药学干预对克州地区高脂血症患者用药依从性及治疗效果的影响

Effects of pharmaceutical intervention on medication adherence and therapeutic outcome of patients with hyperlipidemia in Kizilsu Kyrgyz Autonomous Prefecture

摘要:

目的 探讨药学干预对克州地区高脂血症患者用药依从性及治疗效果的影响。方法 选取2021年1月—2021年12月新疆克州人民医院收治的100例高脂血症患者，按随机数字表法将患者分为干预组和对照组，每组50例。对照组接受常规调脂治疗，干预组接受调脂治疗和药学干预。比较两组调脂达标率、血脂［甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白A、载脂蛋白B］、服药依从性、疾病认知及不良反应的差异。结果 干预组干预6、9、12个月时调脂治疗达标率均高于对照组（P <0.05）。干预组与对照组干预前及干预后1、3、6、9、12个月Morisky服药依从性评分、疾病认知评分、TC、TG、HDL-C、LDL-C、载脂蛋白A、载脂蛋白B比较，结果 ①不同时间点Morisky服药依从性评分、疾病认知评分、TC、TG、HDL-C、LDL-C、载脂蛋白A、载脂蛋白B比较，差异均有统计学意义（P <0.05）；②干预组与对照组Morisky服药依从性评分、疾病认知评分、TC、TG、HDL-C、LDL-C、载脂蛋白A、载脂蛋白B比较，差异均有统计学意义（P <0.05）；③两组Morisky服药依从性评分、疾病认知评分、TC、TG、HDL-C、LDL-C、载脂蛋白A、载脂蛋白B变化趋势比较，差异均有统计学意义（P <0.05）。干预组总不良反应发生率低于对照组（P <0.05）。结论 药学干预可提高克州地区高脂血症患者用药依从性、疾病认知及调脂治疗达标率，延缓动脉粥样硬化进展，保障用药安全。

Abstract:

Objective To investigate the effects of pharmaceutical intervention on medication adherence and therapeutic outcome of patients with hyperlipidemia in Kizilsu Kyrgyz Autonomous Prefecture.Methods The 100 patients with hyperlipidemia admitted to Kizilsu Kyrgyz Autonomous Prefecture People's Hospital from January 2021 to December 2021 were selected and divided into the intervention group and the control group by the random number table method, with 50 cases in each group. The control group received the routine lipid-regulating therapy, and the intervention group received the lipid-regulating therapy and pharmaceutical intervention. The differences in the lipid control rate, levels of blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A, and apolipoprotein B], medication adherence, disease cognition and adverse reactions were compared between the two groups.Results After 6, 9 and 12 months of intervention, the lipid control rates of the intervention group were all higher than those of the control group (P < 0.05). The Morisky Medication Adherence Scale scores, disease cognition scores, and levels of TC, TG, HDL-C, LDL-C, apolipoprotein A and apolipoprotein B before and 1 month, 3 months, 6 months, 9 months and 12 months after the intervention in the intervention group and the control group were compared, and the results revealed that they were different among the time points (P < 0.05) and between the groups (P < 0.05), and that the change trends of them were different between the two groups (P < 0.05). The overall incidence of adverse reactions in the intervention group was lower than that in the control group (P < 0.05).Conclusions Pharmaceutical intervention can improve the medication adherence, disease cognition and the lipid control rate in patients with hyperlipidemia in Kizilsu Kyrgyz Autonomous Prefecture. Besides, it delays the progression of atherosclerosis and ensures medication safety.